The case for adjuvant therapy for prostate cancer

Area of Science:

• Oncology
• Urology

Background:

• Prostate cancer management has evolved, with increasing focus on adjuvant therapies.
• Experience from other epithelial neoplasms informs prostate cancer treatment strategies.

Purpose of the Study:

• To review the rationale for adjuvant therapy in prostate cancer.
• To discuss the potential benefits of adjuvant treatments based on current evidence.

Main Methods:

• Selective review of literature on adjuvant therapy in epithelial neoplasms.
• Discussion of chemotherapy's role in advanced prostate cancer.

Main Results:

• Adjuvant therapy can benefit high-risk prostate cancer patients (Gleason score ≥8, PSA >20 ng/ml, positive margins, etc.).
• Hormonal adjuvant treatment improves disease-free and overall survival after radiotherapy.
• Adjuvant radiotherapy and hormonal therapy post-prostatectomy reduce recurrence.
• Chemotherapy shows promise for advanced prostate cancer, improving survival.

Conclusions:

• A multimodality approach involving surgical urology, radiation therapy, and medical oncology is essential.
• Realizing the full potential of adjuvant therapy requires collaborative efforts across disciplines.